What are the recommended treatments for cough in patients with pulmonary fibrosis?

Treatment of Cough in Pulmonary Fibrosis

For patients with pulmonary fibrosis and chronic cough, first rule out common treatable causes (GERD, upper airway cough syndrome, asthma), then for refractory cough consider gabapentin or speech pathology therapy, and reserve opiates for severe cases affecting quality of life when other treatments fail. 1

Initial Assessment and Common Causes

Before attributing cough solely to interstitial lung disease (ILD), you must systematically evaluate and treat common etiologies that frequently coexist:

• Assess for disease progression or complications: Check for worsening ILD, drug side effects from immunosuppressive therapy, or pulmonary infection 1
• Evaluate for gastroesophageal reflux disease (GERD): Present in up to 50% of IPF patients, often asymptomatic 2
• Consider upper airway cough syndrome (previously postnasal drip)
• Rule out asthma or bronchospasm
• Review medications: ACE inhibitors and other drugs can cause cough

Important Caveat on GERD Treatment

For IPF patients with chronic cough and a negative workup for acid reflux, do NOT prescribe proton pump inhibitors 1. This represents a shift from older practices and reflects evidence that PPIs without documented reflux provide no benefit and carry risks (pneumonia, osteoporosis).

What NOT to Use

The 2018 CHEST guidelines explicitly recommend against several therapies:

• Inhaled corticosteroids: Not routinely prescribed for sarcoidosis-associated cough (Grade 2C) 1
• Thalidomide: Despite one positive RCT, the guideline panel voted against recommending it due to significant side effects 1
• Cyclophosphamide or mycophenolate: Not supported for treating cough in scleroderma-associated ILD 1

Refractory Cough Management

When cough persists despite addressing common causes, follow this algorithmic approach:

First-Line for Refractory Cough

Trial therapies recommended for unexplained chronic cough 1:

• Gabapentin: A neuromodulator that reduces cough reflex sensitivity
• Multimodality speech pathology therapy: Addresses behavioral and sensory components of cough

These recommendations acknowledge the limited evidence base but recognize the significant quality-of-life impairment cough causes in ILD patients (comparable to unexplained chronic cough).

Opiates for Severe, Refractory Cough

When alternative treatments have failed and cough adversely affects quality of life, recommend opiates for symptom control in a palliative care setting 1. This is a consensus-based statement reflecting the reality that some patients need palliation.

Critical Implementation Details:

• Reassess benefits and risks at 1 week, then monthly before continuing 1
• Monitor for side effects: nausea (14%), constipation (21%) 3
• Recent high-quality evidence supports this approach: Low-dose controlled-release morphine (5 mg twice daily) reduced objective cough frequency by 39.4% in IPF patients over 14 days 3

Emerging Evidence: Nalbuphine

The most recent and highest-quality evidence comes from the 2026 CORAL trial 4:

• Nalbuphine extended-release (a κ-opioid receptor agonist/μ-opioid receptor antagonist) showed dose-dependent cough reduction
• At 54 mg and 108 mg twice daily: 53-60% reduction in objective cough frequency (P<0.001) 4
• Better side effect profile than traditional opiates, though nausea, fatigue, constipation, and dizziness still occurred
• This represents the strongest evidence for any pharmacologic intervention in IPF-associated cough, though it's not yet FDA-approved

Disease-Specific Considerations

Idiopathic Pulmonary Fibrosis (IPF)

Cough occurs in up to 80% of IPF patients and predicts disease progression 1. The mechanism involves:

• Mechanical distortion from fibrosis
• Heightened cough reflex sensitivity
• Airway inflammation
• GERD (often asymptomatic)

Pirfenidone (an approved IPF therapy) may reduce objective 24-hour cough counts as a secondary benefit 5, though this is not its primary indication.

Sarcoidosis

Chronic cough affects 50% of patients with pulmonary sarcoidosis and correlates with poor quality of life 1. Cough reflex sensitivity (not lung function or disease severity) predicts cough frequency 1.

Hypersensitivity Pneumonitis

When HP causes cough, treatment requires:

1. Elimination of causative exposure (essential) 6
2. Systemic corticosteroids for those with physiologic impairment (Level of evidence: low; benefit: substantial; Grade B) 6

Practical Algorithm

1. Confirm ILD diagnosis and assess severity
2. Systematically evaluate and treat: GERD (if documented), upper airway issues, asthma, medication causes
3. If cough persists (refractory):
   • Trial gabapentin or speech pathology therapy
   • Consider clinical trial enrollment if available 1
4. For severe cough impairing quality of life:
   • Initiate low-dose opiates (e.g., morphine 5 mg controlled-release twice daily) 3
   • Reassess weekly initially, then monthly
   • Monitor for constipation and nausea
5. Watch for emerging therapies: Nalbuphine ER shows promise but awaits regulatory approval 4

Common Pitfalls

• Don't assume cough is solely from ILD without excluding common causes—this is a diagnosis of exclusion 1
• Don't prescribe PPIs empirically in IPF without documented reflux 1
• Don't use inhaled corticosteroids routinely for sarcoidosis cough 1
• Don't delay palliative care discussions in patients with severe, refractory cough—quality of life matters 1

The evidence base for treating ILD-associated cough remains limited, but the 2018 CHEST guidelines 1 provide the most authoritative framework, supplemented by recent high-quality trials demonstrating efficacy of opiates 3 and nalbuphine 4 for objective cough reduction.